Check out your Company Bowl for anonymous work chats.
Otsuka’s JYNARQUE™ (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Otsuka Encourages Start-Ups to Spark the Next Generation of Innovation and Collaboration in Mental Health Care
Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid
http://glassdoor.com/slink.htm?key=vQg4u
Otsuka And Proteus® Announce The First U.S. FDA Approval of A Digital Medicine System: ABILIFY MYCITE® (aripiprazole tablets with sensor)
FDA Accepts Otsuka’s Resubmission To Support A Regulatory Review Of Tolvaptan In The Treatment Of ADPKD
Science 37 and Otsuka Pharmaceutical Collaborate to Advance Digital Health Innovation with Focus on Technology-Enabled Clinical Trials at Home
Otsuka and Proteus Digital Health® Resubmit Application to FDA For First Digital Medicine
PRESS RELEASES 25 APR 2017: Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialize Vadadustat in Europe, China and Other Territories.
PRESS RELEASES 02 MAY 2017: Otsuka and Lundbeck announce results of brexpiprazole on symptoms of agitation related to Alzheimer’s-type dementia.
